文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

基于计划三维剂量分布提取的剂量组学特征能否改善生化失败无生存预测:基于大型多机构数据集的分析

Do Dosiomic Features Extracted From Planned 3-Dimensional Dose Distribution Improve Biochemical Failure-Free Survival Prediction: an Analysis Based on a Large Multi-Institutional Data Set.
PubMed 文献 · Adv Radiat Oncol · 2023-03-27

该回顾性研究纳入2010至2016年在加拿大Albert接受根治性外照射放疗的1852例局限期前列腺癌患者,用2中心1562例建立3个随机生存森林模型(仅临床特征、临床+等效均匀剂量与肿瘤控制概率、临床+2074个剂量组学特征),另2中心290例独立验证。模型C选出6个剂量组学特征和4个临床特征,验证集C指数0.662,优于模型A的0.653和模型B的0.648,差异有统计学意义但提升幅度有限。

要点

  • 模型C在验证集C指数0.662,高于模型A的0.653和模型B的0.648,差异有统计学意义但提升有限。
  • 模型C从2074个剂量组学特征中选出6个剂量组学特征和4个临床特征作为预后因素。
  • 训练集和验证集4个风险组间差异均有统计学意义。

核心结论

  • 剂量组学包含计划剂量分布中超越常用剂量体积直方图指标的信息。
  • 将预后剂量组学特征纳入生化失败无生存结局模型可带来有统计学意义但幅度有限的性能提升。

研究设计与样本

  • 回顾性研究,纳入2010至2016年在加拿大Albert接受根治性外照射放疗的1852例局限期前列腺癌患者。
  • 来自2个中心的1562例用于建立3个随机生存森林模型:模型A仅含5个临床特征;模型B含5个临床特征、等效均匀剂量和肿瘤控制概率;模型C含5个临床特征和从临床靶区与计划靶区计划剂量分布提取的2074个剂量组学特征并进一步筛选预后特征。
  • 模型A和B未进行特征选择;另2个中心的290例用于独立验证。
  • 采用Harrell一致性指数(C-index)评价3个模型性能,并用单因素重复测量方差分析及事后配对t检验比较。

主要发现

  • 模型C选出6个剂量组学特征和4个临床特征作为预后因素。
  • 训练集和验证集4个风险组间差异均有统计学意义。
  • 训练集袋外样本C指数:模型A为0.650、模型B为0.648、模型C为0.669。
  • 验证集C指数:模型A为0.653、模型B为0.648、模型C为0.662。
  • 模型C在统计上显著优于模型A和模型B,但提升幅度有限。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The objective of this work was to investigate whether including additional dosiomic features can improve biochemical failure-free survival prediction compared with models with clinical features only or with clinical features as well as equivalent uniform dose and tumor control probability. METHODS AND MATERIALS: This retrospective study included 1852 patients who received diagnoses of localized prostate cancer between 2010 and 2016 and were treated with curative external beam radiation therapy in Albert, Canada. A total of 1562 patients from 2 centers were used for developing 3 random survival forest models: Model A included only 5 clinical features; Model B included 5 clinical features, equivalent uniform dose, and tumor control probability; and Model C considered 5 clinical features and 2074 dosiomic features derived from the planned dose distribution of the clinical target volume and planning target volume with further feature selection to determine prognostic features. No feature selection was performed for models A and B. Two hundred ninety patients from another 2 centers were used for independent validation. Individual model-based risk stratification was examined, and the log-rank tests were performed to test statistically significant differences between the risk groups. The 3 models' performances were evaluated using Harrell's concordance index (C-index) and compared using one-way repeated-measures analysis of variance with post hoc paired t test. RESULTS: Model C selected 6 dosiomic features and 4 clinical features to be prognostic. There were statistically significant differences between the 4 risk groups for both training and validation data sets. The C-index for the out-of-bag samples of the training data set was 0.650, 0.648, and 0.669 for models A, B, and C, respectively. The C-index for the validation data set for models A, B, and C was 0.653, 0.648, and 0.662, respectively. Although gains were modest, Model C was statistically significantly better than models A and B. CONCLUSIONS: Dosiomics contain information beyond common dose-volume histogram metrics from planned dose distributions. Incorporation of prognostic dosiomic features in biochemical failure-free survival outcome models can lead to statistically significant although modest improvement in performance.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Sun L, Burke B, Quon H, et al. Do Dosiomic Features Extracted From Planned 3-Dimensional Dose Distribution Improve Biochemical Failure-Free Survival Prediction: an Analysis Based on a Large Multi-Institutional Data Set. Adv Radiat Oncol. 2023. PMID: 37216005. doi:10.1016/j.adro.2023.101227

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。